A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). (Q33396382)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Joyce M van Dodewaard-de Jong

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John M H de Klerk

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Haiko J Bloemendal

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bart P J van Bezooijen

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marie J de Haas

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard H Wilson

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joe M O'Sullivan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

27 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1990-1998

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Management of the spectrum of hormone refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1883-0

21 January 2018

Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

186Re-etidronate in breast cancer patients with metastatic bone pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioisotopes for metastatic bone pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-1883-0

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33396382&oldid=2195320852"